How Atorvastatin Binds to HMG-CoA Reductase
Atorvastatin, a statin drug sold as Lipitor, inhibits HMG-CoA reductase—the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, converting HMG-CoA to mevalonate. It binds competitively to the enzyme's active site, mimicking the natural substrate HMG-CoA and blocking its access.[1]
The binding relies on atorvastatin's pharmacophore: a 3,5-dihydroxyheptanoic acid chain resembling HMG-CoA's structure. In its active, dianionic form at physiological pH, the drug forms key hydrogen bonds with enzyme residues:
- The 3-hydroxy and carboxylate groups interact with Ser684, Asp690, and Lys691 in the active site.
- The pyrrole ring of atorvastatin stacks against hydrophobic residues like Val683 and Ala856, stabilizing the complex.[2][3]
Crystal structures (e.g., PDB 1HWK) show atorvastatin adopting a compact, extended conformation that fits the L-shaped active site pocket. The enzyme's catalytic triad (Asp767, Lys735, Glu559) positions the substrate for hydride transfer from NADPH, but atorvastatin occupies this space without reacting, halting the reaction.[4]
This tight binding yields a Ki of about 7 nM, with residence time extended by slow off-rates, explaining its potency.[5]
Why Does This Binding Inhibit Cholesterol Production?
By occupying the active site, atorvastatin prevents HMG-CoA from binding and undergoing reduction. This depletes mevalonate, downregulating the mevalonate pathway and reducing LDL cholesterol synthesis in the liver. Cells compensate by upregulating LDL receptors, clearing more circulating LDL.[1][2]
How Does Atorvastatin Compare to Other Statins in Binding?
Atorvastatin binds more tightly than simvastatin (Ki ~20 nM) due to extra fluorine substituents enhancing hydrophobic interactions and polar contacts. Rosuvastatin uses a similar pharmacophore but adds a nitrogen heterocycle for distinct H-bonding with Lys691, achieving comparable affinity (Ki ~5 nM).[3][6]
| Statin | Key Binding Features | Ki (nM) |
|--------|----------------------|---------|
| Atorvastatin | Pyrrole ring, fluorophenyls | 7 |
| Simvastatin | Decalin ring, ester | 20 |
| Rosuvastatin | Triazole, fluorophenyl | 5 |
| Pravastatin | Open chain, fewer hydrophobics | 150 |
What Structural Mutations Affect Binding?
Mutations like Asp690Asn in HMG-CoA reductase reduce atorvastatin affinity by 10-fold, disrupting H-bonding and causing statin resistance in some patients. These rare variants highlight binding precision.[7]
When Do Atorvastatin Patents Expire?
Core patents on atorvastatin expired in 2011 in the US, enabling generics. DrugPatentWatch tracks remaining formulation patents expiring through 2030, including pediatric exclusivity until 2022 (already lapsed).[8]
Sources
[1] Istvan & Deisenhofer, Science (1998)
[2] Istvan et al., J Biol Chem (2001)
[3] Istvan, Atheroscler Suppl (2003)
[4] PDB 1HWK
[5] Lu et al., J Med Chem (2006)
[6] Martin et al., J Med Chem (2004)
[7] Thompson et al., Atherosclerosis (2008)
[8] DrugPatentWatch.com - Lipitor Patents